| 13.6 -0.2 (-1.45%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 16.36 |
1-year : | 17.57 |
| Resists | First : | 14 |
Second : | 15.05 |
| Pivot price | 13.56 |
|||
| Supports | First : | 12.31 |
Second : | 10.25 |
| MAs | MA(5) : | 13.94  |
MA(20) : | 13.5 |
| MA(100) : | 13.47 |
MA(250) : | 12.85 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 51.2 |
D(3) : | 60 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 17.14 | Low : | 7.05 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ENTA ] has closed below upper band by 47.3%. Bollinger Bands are 41.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.93 - 14.01 | 14.01 - 14.08 |
| Low: | 13.23 - 13.33 | 13.33 - 13.41 |
| Close: | 13.46 - 13.62 | 13.62 - 13.73 |
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Thu, 27 Aug 2026
Enanta Pharmaceuticals Inc. (ENTA) Peer Comparison – Compare with Others - Value Research
Thu, 27 Aug 2026
Enanta Pharma Market Sentiment - Benzinga España
Thu, 20 Aug 2026
Farallon Capital Management Trims Enanta Pharmaceuticals (ENTA) Stake -- Shares Trade 65% Above GF Value - GuruFocus
Thu, 20 Aug 2026
Deep Track Capital, LP Trims Enanta Pharmaceuticals Inc (ENTA) S - GuruFocus
Mon, 17 Aug 2026
Enanta Pharma (ENTA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 94.3 (%) |
| Shares Short | 2,590 (K) |
| Shares Short P.Month | 2,580 (K) |
| EPS | -2.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.47 |
| Profit Margin | -96.9 % |
| Operating Margin | -120.1 % |
| Return on Assets (ttm) | -12.3 % |
| Return on Equity (ttm) | -70.2 % |
| Qtrly Rev. Growth | -21.7 % |
| Gross Profit (p.s.) | 2.24 |
| Sales Per Share | 2.24 |
| EBITDA (p.s.) | -1.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -5.62 |
| PEG Ratio | 0 |
| Price to Book value | 3.91 |
| Price to Sales | 6.07 |
| Price to Cash Flow | -11.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|